Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Franco Valle as Principal Accounting Officer
On January 1, 2020, Eidos Therapeutics, Inc. (the "Company") appointed Franco
Valle as the Company's Senior Vice President, Finance and principal accounting
officer, effective immediately. Mr. Valle succeeds Christine Siu as the
Company's principal accounting officer.
Mr. Valle, 39, joined the Company as its Vice President, Finance in March, 2018.
Before he joined the Company from July 2016 to January 2018 he worked at Iovance
Biotherapeutics, Inc. as the Controller and principal accounting officer. Prior
thereto, from May 2012 through April 2016 Mr. Valle worked at Pharmacyclics,
Inc. in various positions, including most recently as the senior director of
accounting. Prior thereto, Mr. Valle was the SEC reporting manager of Callidus
Software, Inc. from October 2011 to May 2012. From July 2005 to October 2011,
Mr. Valle worked at PricewaterhouseCoopers LLP in the life science, biotech and
venture capital group. Mr. Valle is a certified public accountant and a graduate
of San Jose State University.
There are no arrangements or understandings between Mr. Valle and any other
persons pursuant to which he was appointed as principal accounting officer of
the Company, and Mrs. Valle has no family relationship with any director or
executive officer of the Company. Mr. Valle is not a party to any current or
proposed transaction with the Company for which disclosure would be required
under Item 404(a) of Regulation S-K.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
EIDOS THERAPEUTICS, INC. 
